N
KALV

Nuveen’s KalVista Pharmaceuticals KALV Stock Holding History

Nuveen’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Sell
106,864
-265
-0.2% -$4.27K ﹤0.01% 2250
2025
Q4 		$1.73M Buy
107,129
+27,371
+34% +$362K ﹤0.01% 2349
2025
Q3 		$971K Buy
79,758
+11,219
+16% +$155K ﹤0.01% 2638
2025
Q2 		$775K Buy
68,539
+31,218
+84% +$382K ﹤0.01% 2711
2025
Q1 		$4.93M Sell
37,321
-43,122
-54% -$440K ﹤0.01% 1935
2024
Q4 		$681K Hold
80,443
– – ﹤0.01% 2875
2024
Q3 		$932K Hold
80,443
– – ﹤0.01% 2795
2024
Q2 		$948K Buy
80,443
+9,376
+13% +$109K ﹤0.01% 2750
2024
Q1 		$843K Hold
71,067
– – ﹤0.01% 2767
2023
Q4 		$871K Buy
71,067
+10,115
+17% +$92K ﹤0.01% 2798
2023
Q3 		$587K Sell
60,952
-831
-1% -$8.49K ﹤0.01% 2788
2023
Q2 		$556K Hold
61,783
– – ﹤0.01% 2890
2023
Q1 		$485K Sell
61,783
-7,163
-10% -$53.4K ﹤0.01% 2813
2022
Q4 		$982K Sell
68,946
-10,832
-14% -$58K ﹤0.01% 2683
2022
Q3 		$1.16M Buy
79,778
+535
+0.7% +$7.48K ﹤0.01% 2679
2022
Q2 		$779K Buy
79,243
+15,338
+24% +$169K ﹤0.01% 2895
2022
Q1 		$962K Buy
63,905
+805
+1% +$11.6K ﹤0.01% 2828
2021
Q4 		$796K Sell
63,100
-59,022
-48% -$940K ﹤0.01% 2929
2021
Q3 		$2.35M Sell
122,122
-237
-0.2% -$4.8K ﹤0.01% 2597
2021
Q2 		$2.93M Buy
122,359
+39,269
+47% +$1.03M ﹤0.01% 2530
2021
Q1 		$1.3M Sell
83,090
-748
-0.9% -$19.7K ﹤0.01% 2802
2020
Q4 		$1.59M Sell
83,838
-26,953
-24% -$462K ﹤0.01% 2620
2020
Q3 		$1.4M Buy
110,791
+256
+0.2% +$3.2K ﹤0.01% 2535
2020
Q2 		$1.34M Buy
110,535
+53,863
+95% +$573K ﹤0.01% 2496
2020
Q1 		$433K Buy
56,672
+17,193
+44% +$232K ﹤0.01% 2818
2019
Q4 		$703K Buy
39,479
+7,279
+23% +$95K ﹤0.01% 2812
2019
Q3 		$374K Sell
32,200
-29,706
-48% -$480K ﹤0.01% 3019
2019
Q2 		$1.37M Buy
+61,906
New +$1.45M ﹤0.01% 2610

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's KALV Position: Q1 2026 in Review

Nuveen reduced its KalVista Pharmaceuticals (KALV) stake by 0.25% in Q1 2026, selling an estimated $4.27K and leaving 106,864 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Nuveen first reported a position in KALV in Q2 2019 and has held it in 28 quarters since. The position peaked at $4.93M in Q1 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Nuveen held 106,864 shares of KalVista Pharmaceuticals worth $2.15M as of Q1 2026.
  • Nuveen sold 265 KalVista Pharmaceuticals shares in Q1 2026, an estimated $4.27K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2250 holding.
  • Nuveen first reported a position in KalVista Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's KalVista Pharmaceuticals position peaked at $4.93M in Q1 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.